1[1]Hanefeld M. Pharmacokinetics and clinical efficacy of pioglitazone [J]. IntJ ClinPract, 2001, 121 (suppl): s19
2[2]Maeshiba Y, Kiyota Y, Yamashita K, et al. Disposition of the new antidiabetic agent pioglitazone in rats, dogs, andmonkeys [J]. Arzneimittelforschung, 1997, 47 (1): 29
3[3]KrieterPA, CollettiAE, Doss GA, etal. Disposition andmetabolism of the hypoglycemic agent pioglitazone in rats [J].DrugMetabDispos, 1994, 22 (4): 625
4[4]Kiyota Y, Kondo T, Maeshiba Y, et al. Studies on the metabolism of the new antidiabetic agent pioglitazone identification of metabolites in rats and dogs [J]. Arzneimittelforschung,1997, 47 (1): 22
5[5]Steven P. Tanis, Timothy T, Parker, et al. Synthesis and biological activity of metabolites of the antidiabetic, antihyperglycemic agent Pioglitazone [J]. J Med Chem, 1996, 39(26): 5053
6[6]Eckland DA, Danhof M. Clinical pharmacokinetics of pioglitazone [J]. ExpClin Endocrino, 2002, 108 (suppl.): s234
7[7]Sahi J, Black CB, Hamilton GA, et al. Comparative efffects of thiazolidinediones on in vitro P450 enzyme induction and inhibition [J]. DrugMetabDispos, 2003, 31 (4): 439
8[8]Nowak SN, Edwards DJ, Clarke A, etal. Pioglitazone: effect on CYP 3A4 activity [J]. J Clin Pharmacol, 2002, 42(12): 1299
9[9]Hiraga K. Clinical Phase 1 study of AD-4833: Single-dose and repeated-dose studies [J]. Jpn J Clin Exp Med, 1997, 74(12): 1184
3CHILCOTr J, TAPPENDEN P, JONES, et al. A sys- tematic review of the clinical effectiveness of pioglita- zone in the treatment of type 2 diabetes mellitus [J].Clinical Therapy ,2001,23 ( 11 ) : 1792 - 1823.
4MAEDA K. Hepatocellular injury in a patient receiv- ing pioglitazone [ J]. Ann Intern Med,2001,135 (4) : 306.
5MAY L, LEFKOWITCH J, KRAM M, et al. Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy[ J]. Ann Intern Med,2002,136(6) :449 -452.
6HANEFELD M. Pharmacokinetics and clinical effica- cy of pioglitazone [ J]. Int J Clin Pract, 2001,121 (suppl) : s19.
7NOZAWA T, SUGIURA S, NAKAJIMA M, et al. Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity [ J ]. Drug Metab Dispos ,2004,32( 3 ) :291 - 294.
8CHANG C, PANG K S, SWAAN P W, et al. Compar- ative pharmacophore modeling of organic anion trans- porting polypeptides: a meta - analysis of rat Oatpl al and human OATP1B1 E J]. J Pharmacol Exp Ther, 2005,314(2) :533 -541.
9YVONNE Y L, HIDEAKI O, HUANG Yong, et al. Multiple transporters affect the disposition of atorvas- tatin and its two active hydroxy metabolites: applica- tion of in vitro and ex situ systems[J].J Pharmacol Exp Ther,2006,316(2):762 -771.
10MAESHIBA Y, KIYOTA Y, YAMASHITA K, et al. Disposition of the new anfidiabetic agent pioglitazone in rats, dogs, and monkeys [ J ]. Arzneimittelfors- chung, 1997,47 ( 1 ) :29 - 35.
